This is the right side and sorry before wrote under Alan...

This is the right side and sorry before wrote under Alan Kohler....

Note: I write the following based on my 20 years of medical research experience and commercialization of Diagnostic Kits.

Since I involved in other bio-marker development, I can do calculations based on duplicated analysis revenue. Generally, people get tumors and mostly they are not the malignant type to prove they have to do the tests. BD1 method is well advanced and detects very early stage. When they sell the kit for the purpose they can make a very good return. I expect some agreement with diagnostic kit distributors with BD1 and this may happen any time. When the kit becomes popular return will be very high and early-stage expect 10% of the following. Always profit in this area at least 200% and same as pharmaceuticals.
In Australia only can make Revenue

100,000 subjects x $200 = 20000000 = 20 million

USA1000000 x $200 = 200 Million

Europe1000000 x $200 = 200 million

1) In Australia alone, 20,000 people diagnosed with breast cancer every year. The accuracy of the method is excellent and also the method is working on other cancers and already proved for ovarian cancer.

2) In addition during the cancer treatment can monitor the progress of the patients using this method and the kit method can be used anywhere and no need high-tech instruments. Just a kit.

3) Prognosis of cancer (before getting symptoms) do the blood test (as reach_K wrote, TEST bi-annual or annually) HUGE SAVINGS TO GOVERNMENT in Cancer treatment.

4) Definitions:
Diagnosis: The identification of the nature of an illness or other problem by examination of the symptoms.
Prognosis: Before getting symptom/s just identify the problem. The cancer is caught early the prognosis is excellent.